<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Novartis AG. &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/novartis-ag/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 03 Aug 2021 02:09:27 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Novartis AG. &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>全球重症肌无力市场研究报告预测至2023年</title>
		<link>https://www.yuanzhezixun.com/quanqiuzhongzhengjiwulishichangyanjiubaogaoyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 23 Apr 2019 06:33:55 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Alexion Pharmaceuticals]]></category>
		<category><![CDATA[and Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[CSL Behring]]></category>
		<category><![CDATA[GE Healthcare]]></category>
		<category><![CDATA[Grifols S.A.]]></category>
		<category><![CDATA[KONINKLIJKE PHILIPS N.V.]]></category>
		<category><![CDATA[Medtronic PLC]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Shire]]></category>
		<category><![CDATA[重症肌无力]]></category>
		<category><![CDATA[重症肌无力市场]]></category>
		<category><![CDATA[重症肌无力市场报告]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19509</guid>

					<description><![CDATA[重症肌无力（MG）是一种免疫系统神经肌肉疾病，其主要作用是减少AChRs在肌肉终板膜上的会聚。北美和拉丁美洲共同致力于全球重症肌无力市场的发展。与此同时，欧洲和亚太地区在价值方面占据第二和第三位。最近重症肌无力的优势已经显着上升，这促使治疗要求急剧增加。预计全球重症肌无力市场在预计期间（2018-2023）的年增长率为9.61％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>全球精准医药市场（2018-2023）</title>
		<link>https://www.yuanzhezixun.com/quanqiujingzhunyiyaoshichang2018-2023/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 16 Apr 2019 03:21:53 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Almac Group]]></category>
		<category><![CDATA[GE Healthcare]]></category>
		<category><![CDATA[GlaxoSmithKline (GSK)]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Quest Diagnostics]]></category>
		<category><![CDATA[Randox Laboratories]]></category>
		<category><![CDATA[Teva Pharmaceutical industries]]></category>
		<category><![CDATA[精准医药]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19051</guid>

					<description><![CDATA[全球精准医药市场受益于生命科学行业的进步。尽管处于初期阶段，但由于有可能治疗和治疗慢性疾病，因此靶向治疗在未来几年中有很大的机会成功取得巨大成功。因此预计2018年至2023年期间市场将以11.60％的复合年增长率（CAGR）扩张，到2023年将产生88.25亿美元的收入。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>自闭症和治疗市场报告 &#8211; 全球预测至2023年</title>
		<link>https://www.yuanzhezixun.com/zibizhenghezhiliaoshichangbaogao-quanqiuyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Fri, 11 Jan 2019 03:02:30 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[ASD]]></category>
		<category><![CDATA[Autism Disorder]]></category>
		<category><![CDATA[Autism treatment]]></category>
		<category><![CDATA[Bristol-Myers Squibb and Otsuka Holdings Co.]]></category>
		<category><![CDATA[Consern Pharma Private Limited]]></category>
		<category><![CDATA[Coronis Partners Ltd.]]></category>
		<category><![CDATA[Curemark LLC]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[Heptares Therapeutics Limited]]></category>
		<category><![CDATA[Intra-Cellular Therapies Inc.]]></category>
		<category><![CDATA[Johnson & Johnson Services]]></category>
		<category><![CDATA[Merck & CO Inc.]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Saniona AB]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Ltd]]></category>
		<category><![CDATA[普遍发育障碍]]></category>
		<category><![CDATA[自闭症]]></category>
		<category><![CDATA[自闭症谱系障碍]]></category>
		<category><![CDATA[阿斯伯格综合症]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16956</guid>

					<description><![CDATA[预计2017 - 2023年期间全球自闭症和治疗市场将以4.37％的复合年增长率增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>弱视市场研究- 全球预测至2023年</title>
		<link>https://www.yuanzhezixun.com/ruoshishichangyanjiu-quanqiuyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Thu, 03 Jan 2019 04:56:52 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Amblyoptica (Holding) Pty Ltd]]></category>
		<category><![CDATA[Amblyotech]]></category>
		<category><![CDATA[Carl Zeiss AG]]></category>
		<category><![CDATA[Cooper Vision]]></category>
		<category><![CDATA[eye disorder]]></category>
		<category><![CDATA[Fresnel Prism and Lens Co.]]></category>
		<category><![CDATA[Good-Lite Co]]></category>
		<category><![CDATA[Hilco Vision]]></category>
		<category><![CDATA[HOYA Corporation]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Krafty Eye Patches]]></category>
		<category><![CDATA[Mckesson Corporation]]></category>
		<category><![CDATA[Novartis AG.]]></category>
		<category><![CDATA[Vivid Vision]]></category>
		<category><![CDATA[弱视]]></category>
		<category><![CDATA[弱视治疗市场]]></category>
		<category><![CDATA[阿托品滴眼液]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=16926</guid>

					<description><![CDATA[弱视患者占世界婴儿人口的2％至3％。全球弱视市场主要受到白内障，青光眼，黄斑变性和其他屈光不正等眼科疾病发病率上升的推动。随着眼科疾病的日益普及，对疾病的正确治疗的需求日益增加。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
